Alvotech develops and manufactures biosimilar medicines—lower-cost versions of complex biologic drugs—for global markets. Headquartered in Iceland, it pursues a vertically integrated model spanning cell-line development through fill-finish manufacturing, while partnering with commercial distributors for sales. Its pipeline targets areas such as autoimmune disease, ophthalmology, osteoporosis, and oncology, aiming to broaden access to affordable biologics.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 173.2 | — | 32 | — |
| Q3 2025 | 113.7 | — | -5.3 | — |
| Q4 2025 | 166.6 | — | -108.5 | — |
| Q1 2026 | 105.9 | — | 1 | — |
| Q2 2026 | 105.8 | -38.9% | -66.8 | -308.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Establishment Labs Holdings Inc. (ESTA), Sunrun Inc. (RUN), Formula Systems (1985) Ltd. (FORTY), Alamar Biosciences, Inc. (ALMR), Intuitive Machines, Inc. (LUNR), Palvella Therapeutics, Inc. (PVLA)